Short-term effect of nimotuzumab combined with synchronal radiochemotherapy in treating locally advanced esophageal carcinoma

Fei Lisheng; Meng Lingxin; Zhang Guifang; Meng Qin; Xu Meiling; Ding Zhaojun

doi:10.3760/cma.j.issn.1673-4777.2016.06.016

Abstract：Objective To evaluate the short-term effect of nimotuzumab combined with synchronal radio-chemotherapy in treating locally advanced esophageal carcinoma.Methods Ninty-eight patients with locally advanced esophageal cancer from January 2012 to January 2013 were enrolled and divided into intensity-modulated radiotherapy (IMRT) group (29 cases),synchronal radio-chemotherapy group (44 cases) and nimotuzumab combined with synchronal radio-chemotherapy group (combination group,25 cases).The short-term effect and adverse reactions were observed and compared among groups.Results The total effective rate and 1 year survival rate in IMRT group,synchronal radio-chemotherapy group and combination group were significantly different [69.0％ (20/29) vs81.8％ (36/44) vs 92.0％ (23/25),44.8％ (13/29) vs 61.4％ (27/44) vs 76.0％ (19/25)] (P ＜ 0.05).The incidences of radioactive pneumonia,radioactive esophagitis,and 0-2 grade hematology toxicity were not significantly different (P ＞0.05).The incidence of 3-4 grade hematology toxicity in synchronal radio-chemotherapy group and combination group was significantly higher than that in IMRT group [36.4％ (16/44),48.0％ (12/25) vs 27.6％ (8/29)] (P ＜ 0.05),while no significant difference was found between synchronal radio-chemotherapy group and combination group (P ＞ 0.05).In combination group,5 cases had nausea,3 cases had rashes,2 cases had fever and 1 case had blood pressure drop,the adverse reactions were mild and did not impact the therapy.Conclusion Nimotuzumab combined with synchronal radio-chemotherapy has good effect in treating locally advanced esophageal carcinoma,patients with well tolerance.